Genetically engineered immune cells show promise for fighting relapsed blood cancer

Researchers are presenting preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.

Leave a Reply

Your email address will not be published. Required fields are marked *